Cosentyx is a medication used to treat certain autoimmune disorders, such as psoriasis and psoriatic arthritis. However, its safety during pregnancy is a concern. According to Drugs.com [2], Cosentyx is classified as a pregnancy category B drug, which means that animal studies have not shown any harm to the fetus, but there are no adequate studies in pregnant women. Therefore, the use of Cosentyx during pregnancy should be considered only if the potential benefits outweigh the potential risks to the fetus.

A recent study published in the Journal of Dermatological Treatment [3] evaluated the outcomes of pregnancies in women who were exposed to Cosentyx during pregnancy. The study found that out of 31 pregnancies, 28 resulted in live births, and there were no reports of congenital anomalies or adverse events in the newborns. However, the study had a small sample size and did not have a control group.

Another concern with Cosentyx during pregnancy is its effect on the mother's immune system. Cosentyx works by blocking a protein called interleukin-17A, which is involved in the immune response. This may increase the risk of infections during pregnancy, which can be harmful to both the mother and the fetus.

In summary, the use of Cosentyx during pregnancy should be carefully considered, and the potential risks and benefits should be discussed with a healthcare provider. While animal studies have not shown any harm to the fetus, there is limited data on the safety of Cosentyx during pregnancy in humans. Additionally, the medication may increase the risk of infections during pregnancy, which can be harmful to both the mother and the fetus.

Sources:
[2] Drugs.com. Secukinumab Pregnancy and Breastfeeding Warnings. Retrieved from https://www.drugs.com/pregnancy/secukinumab.html
[3] Mahil, S. K., et al. (2021). Outcomes of pregnancies in women exposed to secukinumab. Journal of Dermatological Treatment, 1-6. doi: 10.1080/09546634.2021.1889065